Collaboration Plan Clause Samples

Collaboration Plan. The Collaboration Plan as described in Schedule 18 (Technical Requirements) is specified in Appendix 11, as attached and forming part of this Schedule, and shall be amended or supplemented by the Contractor as required in accordance with Schedule 18 and in accordance with the procedure set out in Schedule 5 (Design and Plan Certification Process and Review Procedure).

Collaboration Plan. The initial Collaboration Plan is described in Exhibit D. The Steering Committee shall prepare an amended Collaboration Plan no later than [*] and every [*] thereafter, during the Contract Period. Such amended Collaboration Plans shall be appended to Exhibit D and made part of this Agreement.

Collaboration Plan. The research and preclinical Development activities of the Parties with respect to the Collaboration Program will be described in a “Collaboration Plan,” an initial version of which is attached hereto as Exhibit 2.1(b). The Collaboration Plan will include a budget for the remaining portion of the Calendar Year in which this Agreement is executed and the next succeeding Calendar Year, and a projected budget for the next Calendar Year thereafter or until the end of the Collaboration Program Term if shorter. The Collaboration Plan will be reviewed as necessary at each meeting of the JSC, and at any other time upon the request of either Party, and will be modified as appropriate at the direction of the JSC to reflect material scientific, commercial and other developments. In all events, the Collaboration Plan will be consistent and not conflict with the terms of this Agreement.

Collaboration Plan. (a) The Parties shall establish a research pre-clinical and clinical development plan for each Collaboration Product, as may be supplemented and amended from time to time by the Joint Steering Committee, as described in Section 2.2.2.(a) (each, a “Collaboration Plan”). The initial Collaboration Plan for the Initial Collaboration Products shall be attached hereto as Exhibit 3.1.2.(a).1, Exhibit 3.1.2.(a).2, Exhibit 3.1.2.(a).3 and Exhibit 3.1.2.(a).4. Subject to Servier’s exercise of the Servier Collaboration Option in accordance with Section 3.1.1.(c), the

Collaboration Plan. The Parties will conduct each Program in accordance with the Collaboration Plan. Unless decided otherwise by the JRC, the Collaboration Plan will be updated annually by the JRC. The Collaboration Plan for the HB700 Program and, if Roche exercises the Option pursuant to Section 2.3.2, the *** Program will set forth: (a) the scope of the Program and the resources that will be dedicated to the activities contemplated within the scope of the Program, including the responsibilities of each Party; (b) specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JRC as research progresses; (c) criteria for progression of Collaboration Compounds during the preclinical stages up to and including IND submission (“Selection Criteria”); (d) contents of the respective data packages that Parties shall provide to the JRC (“Data Packages”); and (e) budgets for the activities under the scope of the Program prior to Roche Go-Decision with respect to such Program, including a budget for the Trial Costs (“Collaboration Budget”). An initial Collaboration Budget for the HB700 Program and the *** Program, including the activities to be conducted pursuant to the Pre-Option *** Collaboration Plan is attached as Appendix 3.2.3(A). Prior to the Option Exercise, the *** Program will be conducted pursuant to the Pre-Option *** Collaboration Plan. The JRC shall review the Collaboration Plan on an ongoing basis and may amend such plan. Any such changes shall be reflected in written amendments to the Collaboration Plan. The initial Collaboration Plan, hereto attached as Appendix 3.2.3(B), relates to the HB700 Program and Initial Compounds (the “HB700 Collaboration Plan”) and includes a high-level plan for the First Human Trial for an Initial Compound, including clinical Endpoints, subject to further revisions. If Roche exercises the Option as set forth in Section 2.3.2, the Collaboration Plan shall be updated to include further development of the *** Program through a First Human Trial for an Option Compound, in the same manner as for the HB700 Program, with the Parties having the same responsibilities with respect to the *** Program as for the HB700 Program.

Collaboration Plan. The Parties will carry out the Collaboration pursuant to a written collaboration plan, which sets forth the specific development activities, required resources, and target timelines for the Collaboration (the “Collaboration Plan”); except as may be set forth in the Collaboration Plan, iBio will perform all activities required by the Collaboration Plan. The initial Collaboration Plan, as agreed between the Parties, is attached hereto as Exhibit A (Collaboration Plan). The Parties may agree in writing on updates or amendments to the Collaboration Plan. The Collaboration Plan shall continue for the term set forth therein or terminate upon mutual agreement of the Parties. In the event of a conflict between the main body of this Agreement and the Collaboration Plan, the terms of the main body of this Agreement shall control.

Collaboration Plan. The initial collaboration plan for the performance of the Collaboration is attached to this Agreement as Schedule 2.2 (“Collaboration Plan”). The Collaboration Plan will at all times include (a) the Collaboration Activities of each Party, (b) the agreed timelines for the conduct of the Collaboration, and (c) the Collaboration Deliverables, which shall in any event include the Collaboration Trial Data Package.

Collaboration Plan. The Collaboration Plan shall be agreed upon by the Parties prior to execution of this Agreement. The Collaboration Plan shall include specifications for GPC Proprietary Material to be delivered to MORPHOSYS, mutually agreed Success Criteria and specifications for Deliverables for each GPC Target prior to the initiation of work on such GPC Target by MORPHOSYS hereunder. The Collaboration Plan shall also specify time lines for the performance of work by each Party pursuant to the Collaboration Plan. Every four (4) months during the Collaboration Term, or at any time on request of either GPC or MORPHOSYS, the Collaboration Plan shall be updated by MORPHOSYS and GPC and shall be approved by the JSC no later than thirty (30) days before the end of each such four (4) month period. The JSC will consider adjustments in the Collaboration Plan at any time upon the request of GPC or MORPHOSYS.

Collaboration Plan. The Collaboration Plan for the IMMUNOGEN Targets to be pursued during the Collaboration Program shall be agreed upon by the Parties prior to the Effective Date. The Collaboration Plan shall include specifications for IMMUNOGEN Proprietary Material to be delivered to MORPHOSYS, mutually agreed Success Criteria, and specifications for Deliverables for each IMMUNOGEN Target, prior to the initiation of work on such IMMUNOGEN Target by MORPHOSYS hereunder. The Collaboration Plan shall also specify (a) timelines for the performance of work by each Party and (b) milestones and budgets for the performance of work by MORPHOSYS pursuant to the Collaboration Plan. During the Collaboration Term, or at any time on request of either IMMUNOGEN or MORPHOSYS, the Collaboration Plan shall be updated by MORPHOSYS and IMMUNOGEN and shall be approved by the JSC. Nothing in this Agreement shall be construed as an obligation of either Party to perform any additional work beyond the scope of the approved Collaboration Plan.